AML3D Ltd (ASX:AL3) was established in 2014 to commercialise WAM® (Wire Additive Manufacturing), an additive manufacturing technology for the cost-effective production of large, high-performance metal components and structures. The company has reported lower levels of customer conversion in Q1FY22 as a result of the impact of COVID-constrained business development and order completions. AL3 has $5.4m in cash and has been active in developing opportunities in the quarter despite these obvious constraints. The company has advanced connections with academia and will see commercial benefits in both machine sales and technology development from relationships with Deakin University, University of Queensland and RMIT. Boeing, BAe, Keppel and other significant entities are in the process of qualifying parts made using the WAM® process and we expect commercial results to follow.
01 Nov 2021
Q1Fy22 - Leads strong, sales slowed by COVID
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Q1Fy22 - Leads strong, sales slowed by COVID
AML3D Ltd (ASX:AL3) was established in 2014 to commercialise WAM® (Wire Additive Manufacturing), an additive manufacturing technology for the cost-effective production of large, high-performance metal components and structures. The company has reported lower levels of customer conversion in Q1FY22 as a result of the impact of COVID-constrained business development and order completions. AL3 has $5.4m in cash and has been active in developing opportunities in the quarter despite these obvious constraints. The company has advanced connections with academia and will see commercial benefits in both machine sales and technology development from relationships with Deakin University, University of Queensland and RMIT. Boeing, BAe, Keppel and other significant entities are in the process of qualifying parts made using the WAM® process and we expect commercial results to follow.